E2082 Discontinuation May Hit Eisai's Epilepsy Succession
Executive Summary
Fatality of healthy volunteer in early clinical trial prompts halt of all clinical work for candidate anti-epileptic, potentially hitting Eisai's product succession strategy in a core therapeutic area.